Eli Lilly Adds Amylin Receptor Agonists to Camurus Collaboration Agreement

Eli Lilly and Company exercised its option to include amylin receptor agonists in a collaboration and license agreement with Camurus, the Swedish company announced on June 1, 2026. The agreement, originally entered in June 2025, now covers up to four proprietary Lilly drug compounds across three classes: dual GLP-1 and GIP receptor agonists, triple agonists for GLP-1, GIP and glucagon receptors, and amylin receptor agonists.

The option exercise extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology to amylin receptor agonists.

The decision triggers a $5 million initial payment to Camurus. Under the agreement, Camurus is eligible to receive up to $290 million in upfront development and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single digit royalties on product sales.

The amylin receptor agonists are subject to the same milestone payments and royalty levels as the other compounds.

"Lilly's decision to exercise the option validates our technology, broadens our partnership and extends FluidCrystal into the expanding field of amylin therapeutics," said Fredrik Tiberg, President and CEO of Camurus. " Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods from days to months with a single injection.

The technology uses a prefilled syringe or autoinjector pen that transforms into a liquid crystalline gel upon contact with bodily fluids.

The liquid crystalline matrix gradually degrades in tissue to slowly release the drug. , and Australia. Camurus is an international science-led biopharmaceutical company headquartered in Lund, Sweden.